Can breast cancer molecular subtype help to select patients for preoperative MR imaging?

Radiology

Volumn 274, Issue 2, 2015, Pages 352-358

  Grimm, Lars J ^a   Johnson, Karen S ^a   Kelly Marcom, P ^a   Baker, Jay A ^a   Soo, Mary S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER PROGNOSIS; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; INSTITUTIONAL REVIEW; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PECTORALIS MAJOR MUSCLE; PREOPERATIVE EVALUATION; THORAX WALL; TUMOR VOLUME; BREAST NEOPLASMS; CLASSIFICATION; FEMALE; GENETICS; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PATIENT SELECTION; PREOPERATIVE CARE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84921755309     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140594     Document Type: Article

References (36)

1. Jatoi I, Benson JR. The case against routine preoperative breast MRI. Future Oncol 2013;9(3):347-353.
2. Houssami N, Turner R, Morrow M. Pre-operative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg 2013;257(2):249-255.
3. Kuhl C, Kuhn W, Braun M, Schild H. Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back? Breast 2007;16(Suppl 2):S34-S44.
4. Van Goethem M, Tjalma W, Schelfout K, Verslegers I, Biltjes I, Parizel P. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol 2006;32(9):901-910.
5. Young P, Kim B, Malin JL. Preoperative breast MRI in early-stage breast cancer. Breast Cancer Res Treat 2012;135(3):907-912.
6. Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 2009;27(33):5640-5649.
7. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of pre-operative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014; 32(5):392-401.
8. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-752.
9. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19): 10869-10874.
10. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68(9):3108-3114.
11. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329-2334.
12. Fernández-Morales LA, Seguí MA, Andreu X, et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer 2007;7(7):559-564.
13. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011;13(6):221.
14. Lam SW, Jimenez CR, Boven E. Breast cancer classifcation by proteomic technologies: current state of knowledge. Cancer Treat Rev 2014;40(1):129-138.
15. Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008;26(9):1419-1426.
16. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21):2492-2502.
17. Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol 2009;19(4): 204-210.
18. Hayashi Y, Takei H, Nozu S, et al. Analysis of complete response by MRI following neo-adjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer. Oncol Lett 2013;5(1):83-89.
19. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gal-len International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24(9):2206-2223.
20. Moon HG, Han W, Ahn SK, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents Influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg 2013;257(1):133-137.
21. Cruz Ciria S, Jiménez Aragón F, García Mur C, Esteban Cuesta H, Gros Bañeres B. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: Radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype. Radiologia 2013 Jan 4. [Epub ahead of print]
22. Marcos de Paz LM, Tejerina Bernal A, Ar-ranz Merino ML, Calvo de Juan V. Breast MR imaging changes after neoadjuvant chemotherapy: correlation with molecular subtypes. Radiologia 2012;54(5):442-448.
23. De Los Santos J, Bernreuter W, Keene K, et al. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer 2011;11(5):312-319.
24. Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009;16(10):2705-2710.
25. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplifca-tion by fuorescence in situ hybridization. Mayo Clin Proc 2002;77(2):148-154.
26. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):3997-4013.
27. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classifcation in the molecular era: the role of histological grade. Breast Cancer Res 2010;12(4):207.
28. Wu SG, He ZY, Li Q, et al. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Breast 2012;21(5):657-661.
29. Goldstein NS, Decker D, Severson D, et al. Molecular classifcation system identifes invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007; 110(8):1687-1696.
30. Weissenbacher TM, Zschage M, Janni W, et al. Multicentric and multifocal versus unifo-cal breast cancer: is the tumor-node-metastasis classifcation justifed? Breast Cancer Res Treat 2010;122(1):27-34.
31. Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher D W. Pathologic analysis of tumor size and lymph node status in mul-tifocal/multicentric breast carcinoma. Cancer 2002;94(5):1383-1390.
32. Plana MN, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preop-erative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis. Eur Radiol 2012;22(1):26-38.
33. Morrow M. Magnetic resonance imaging for screening, diagnosis, and eligibility for breast-conserving surgery: promises and pitfalls. Surg Oncol Clin N Am 2010; 19(3): 475-492.
34. Theriault RL, Carlson RW, Allred C, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11(7):753-760; quiz 761.
35. Giuliano AE, Hunt KK, Ballman K V, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305(6):569-575.
36. Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with t1-t2 and 1-3 positive lymph nodes: a meta-analysis. PLoS ONE 2013;8(12):e81765.